System Utilization Drives PacBio's 2013 Revenue; Firm Targets Four-Fold Throughput Increase for 2014 | GenomeWeb

Pacific Biosciences reported today that customer use of its PacBio RS II instrument has significantly increased, helping to drive a 54 percent jump in its revenues in the fourth quarter of 2013 to $9.1 million from $5.9 million in the year-ago quarter.

The company recognized revenue in the quarter from the installation of five systems, the same number it booked in Q4 2012, but consumable sales doubled to $2.6 million in the quarter from $1.3 million in Q4 2012.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.